東誠藥業(002675.SZ)：引進前列腺癌顯像診斷核藥產品
格隆匯5月5日丨東誠藥業(002675.SZ)公佈，2019年10月31日，公司披露了《關於簽署戰略合作協議的公告》。戰略合作協議簽署後，經過與北京腫瘤醫院的溝通協商，就公司全資子公司南京江原安迪科正電子研究發展有限公司(“安迪科”)，引進北京腫瘤醫院用於檢測前列腺癌診斷藥物的事項達成協議，並於2020年5月5日正式簽訂了《技術轉讓合同》，公司將獲得18FAL-PSMA-BCH-ZL分子探針產品(“目標產品”)在全球的專利、臨牀開發與註冊、生產和市場銷售的獨家權利。
前列腺癌是一種發自前列腺的惡性腫瘤，大多數前列腺癌生長速度較為緩慢，前列腺癌早期症狀並不明顯。癌細胞可轉移到骨頭和淋巴結等部位，晚期可導致排尿困難、尿血、背痛、骨盆疼痛等症狀。據相關報道，前列腺癌是全球男性第二大常見的腫瘤類型，僅次於肺癌，在男性癌症患者中，前列腺癌死亡率位居第二位。近幾年，由於人口老齡化加劇、生活方式與飲食結構的改變等原因，我國前列腺癌發病率也呈現了明顯上升趨勢。據相關研究發現，前列腺癌早期發現，早期治療，局灶性病變五年生存率接近100%，因此早期診斷對於提升前列腺癌患者生存率具有重要的意義。
由於前列腺特異性膜抗原(PSMA)在前列腺癌表面具有特異性高表達的特點，使其在前列腺癌分子影像學及靶向治療領域具有極為重要的研究價值，特別是核素標記的PSMA小分子抑制劑已在前列腺癌的分子影像學診斷方面顯示出較好的臨牀應用前景。目標產品特異性靶向PSMA，對前列腺癌具有很好的顯像效果，主要用於前列腺癌的篩查、診斷、分期、預後、療效評估、復發監測及指導核素靶向治療等方面，相比於傳統的前臉腺癌診斷方式具有：標記步驟簡單、時間短、標記率較高、空間分辨率高、精準率高等優勢，該產品已在北京腫瘤醫院進行700餘例臨牀試驗，安全性、有效性已得到充分驗證，目前已成為前列腺癌診斷、篩查及手術前的常規檢查之一。
公司通過與北京腫瘤醫院的技術合作，獲取其在前列腺癌相關藥物開發方面的研發優勢，引進對方產品專利及在全球範圍內的臨牀開發、生產和市場銷售權益，對公司短期經營業績不會構成重大影響，但長期來看有助於公司增加核素藥物產品的經營種類，豐富產品管線，拓寬收入和利潤來源，完善精準醫療服務體系，符合公司戰略發展的需要。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
